. Non HDL-c : Downloaded from ijdld.tums.ac.ir at 18:05 IRDT on Friday March 22nd Non HDL LDL. . LDL Non HDL-c

Similar documents
Disclosures. Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA. Learning Objectives. Atherogenesis. Acceptable Values

Comparison of Lipoprotein (a) and Apolipoproteins in Children with and without Familial History of Premature Coronary Artery Disease

The Association of Apolipoprotein B and Low Density Lipoprotein with Cardiovascular Risk Factors in the Thai Population

Non-High-Density lipoprotein cholesterol or Apolipoprotein B in the prediction of myocardial infarction

International Journal of Pharma and Bio Sciences

Downloaded from ijdld.tums.ac.ir at 19:13 IRDT on Friday May 4th 2018

Non High-Density Lipoprotein Cholesterol Versus Low-Density Lipoprotein Cholesterol as a Risk Factor for a First Nonfatal Myocardial Infarction

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

CVD.

Percentile of Serum Lipid Profile in Children at Eastern Iran

Joint role of non-hdl cholesterol and glycated haemoglobin in predicting future coronary heart disease events among women with type 2 diabetes

TRENDS OF LIPID ABNORMALITIES IN PAKISTANI TYPE-2 DIABETES MELLITUS PATIENTS: A TERTIARY CARE CENTRE DATA

Downloaded from ijdld.tums.ac.ir at 16:29 IRDT on Friday March 22nd 2019

Comparison of Abnormal Cholesterol in Children, Adolescent & Adults in the United States, : Review

patient-oriented and epidemiological research

Review of guidelines for management of dyslipidemia in diabetic patients

New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines

Non-HDL Cholesterol and Apolipoprotein B Predict Cardiovascular Disease Events Among Men With Type 2 Diabetes

Predictive value of overweight in early detection of metabolic syndrome in schoolchildren

Is non-hdl-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDLcholesterol?

Cardiovascular Complications of Diabetes

Supplementary Online Content

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials

Metabolic Syndrome among Type-2 Diabetic Patients in Benghazi- Libya: A pilot study. Arab Medical University. Benghazi, Libya

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

ORIGINAL ARTICLE. APO B/APO AI Ratio with Coronary Artery Disease with Normal Lipid Profile in the Indian Population

Impact of metabolic syndrome on hospital in acute myocardial infarction patients

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease. Original Policy Date

The TNT Trial Is It Time to Shift Our Goals in Clinical

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Familial hypercholesterolaemia in children and adolescents

The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India

Raising high-density lipoprotein cholesterol: where are we now?

Lipid and Insulin Levels in Obese Children: Changes with Age and Puberty

Diabetes Day for Primary Care Clinicians Advances in Diabetes Care

Fasting Might Not Be Necessary Before Lipid Screening: A Nationally Representative Cross-sectional Study

Atherosclerosis 207 (2009) Contents lists available at ScienceDirect. Atherosclerosis

Anne Carol Goldberg, MD, FACP, FAHA, FNLA Washington University, St. Louis, MO USA

Lipoprotein (a): Is it important for Friedewald formula?

Research Article Discordance of Non-HDL and Directly Measured LDL Cholesterol: Which Lipid Measure is Preferred When Calculated LDL Is Inaccurate?

Copyright 2017 by Sea Courses Inc.

Established Risk Factors for Coronary Heart Disease (CHD)

Apolipoprotein B and non-high-density lipoprotein cholesterol. and risk of coronary heart disease in Chinese

2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice

High-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease. Original Policy Date

sad EFFECTIVE DATE: POLICY LAST UPDATED:

Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome

Welcome and Introduction

Pattern of dyslipidemia and evaluation of non-hdl cholesterol as a marker of risk factor for cardiovascular disease in type 2 diabetes mellitus

DYSLIPIDAEMIC PATTERN OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. Eid Mohamed, Mafauzy Mohamed*, Faridah Abdul Rashid

References. 1. Personen E, Liuba P. Footprints of atherosclerotic coronary heart disease in children. Rev Port Cardiol 2004;23:

Atherosclerotic Disease Risk Score

Research Article Gender Differences Time Trends for Metabolic Syndrome and Its Components among Tehranian Children and Adolescents

Non-high density lipoprotein cholesterol versus low density lipoprotein cholesterol as a discriminating factor for myocardial infarction

The apolipoprotein story

Association of Current and Past Smoking with Metabolic Syndrome in Men

Macrovascular Management. What s next beyond standard treatment?

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia

Diabetes mellitus type 2 and angina pectoris : novel insights in diagnosis, prognosis and treatment Wiersma, J.J.

Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Original Policy Date

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Achieving Cholesterol Management Goals: Identifying Clinician-Centered Challenges to Optimal Patient Care

Is Universal Pediatric Lipid Screening Justified? YES. Damon Dixon, MD, FAAP Preventative Cardiology March 7 th, 2016

ARTICLE. Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients

LDL . (LDL) Downloaded from ijdld.tums.ac.ir at 12:38 IRST on Friday February 1st 2019 LDL LDL NCEP-ATP-III (LDL) :

Management of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil

Tailored Statin Treatment for Type 2 Diabetes. Han, Ki Hoon Asan Medical Center University of Ulsan

Analysis of the Correlation between Non-high Density Lipoprotein Cholesterol and Coronary Heart Disease in Elderly Chinese

Treatment to reduce cardiovascular risk: multifactorial management

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL

Downloaded from ijem.sbmu.ac.ir at 15: on Saturday August 18th 2018

How to Reduce Residual Risk in Primary Prevention

Accepted Manuscript S (13) Reference: JAC To appear in: Journal of the American College of Cardiology

Qué factores de riesgo lipídicos debemos controlar? En qué medida?

( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )

It is currently estimated that diabetes prevalence by

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution

For personal use only

CVD Prevention, Who to Consider

Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B The Copenhagen City Heart Study

Role of Small Dense Low-Density Lipoprotein in Coronary Artery Disease Patients With Normal Plasma Cholesterol Levels. Small Dense KATAGIRI, MD, FJCC

The National Cholesterol Education Program

What Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives

Relationship of Waist Circumference and Lipid Profile in Children

Prevalence of Metabolic Syndrome and Associations with Lipid Profiles in Iranian Men: A Population-Based Screening Program

On May 2001, the Third Adult

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

Cardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes

Differential impact of aging and gender on lipid and lipoprotein profiles in a cohort of healthy Chinese Singaporeans

Guidelines on cardiovascular risk assessment and management

Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients

Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study

Metabolic Syndrome: Why Should We Look For It?

Epidemiology. Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events

Associations Between Lipid Measures and Metabolic Syndrome, Insulin Resistance and Adiponectin

Transcription:

208-23 (2 ) 0 389 -. Non HDL * Downloaded from ijdld.tums.ac.ir at 8:05 IRDT on Friday March 22nd 209 Non HDL : LDL.. 5 3277 :.. odds ratio Chi-Square %3/9 Non HDL-C %2 LDL-C. %3 : Non-HDL-C LDL-C. (CI %95 :4/-6/2 P=0/00) Non HDL-C odds ratio.(r:0/839 P=0/000). 2/6 (CI %95 :2/-3/2 P=0/0) LDL-C 5/. Non HDL-c : LDL-c Non HDL-c. LDL Non HDL-c Non HDL-c LDL-c : - ( )... : m39sadegh@yahoo.com : 024-727085 : 024-727084 : 455777978

209 Non HDL : Downloaded from ijdld.tums.ac.ir at 8:05 IRDT on Friday March 22nd 209 %25.[].[2] 40 50 36/7.[3 4] HDL-c 7-2.[5] Non HDL-c. [6 7] Non HDL-c [7]. Non -C LDL -C. HDL. 5 3277. 0/. 0/5... 4-2 GOD-PAP 2..[] LDL-C ) Non HDL.[2] (HDL Non HDL Non.[3] HDL Non HDL-c.[4].[5] Non HDL-c -.[6] 2 220 mg/dl Non HDL-c.[7] Non HDL-c. Non HDL-c LDL.[8] ( ) Non HDL LDL.[9] HDL.[0]

( 2 ) 0 389 -. 20 Downloaded from ijdld.tums.ac.ir at 8:05 IRDT on Friday March 22nd 209. Non HDL %20 %5/3.(P=0/00) Non-HDL-C LDL-C.(r:0/83 P=0/000) Non HDL-C (r=0/45 P=0/00) (r=0/35 P=0/00) (r=0/22 P=0/00) P=0/00) (r=0/25 P=0/00). (r=0/33 P=0/00) (r=0/2. Non HDL (%95 CI. 90 :4/-6/2 P=0/00) 5/ mg/dl Non HDL LDL (%95 CI :2/-3/2 P=0/0) 2/6. 60 mg/dl LDL Non BMI HDL-C LDL-C.( 2 ) BMI.(3 ) HDL GOD-PAP (PTA). 0/5. Selectra II, Vital-Lab Co. LDL LDL-C Netherland. mg/dl 60 LDL-C. mg/dl 90 Non HDL-c /5 SPSS Chi-Square. Non HDL-C. 0/05 578 3277 %5 24) %3 9/3.( %37 2/2 LDL-C Non HDL-C.(P< 0/000) 3/9 8/4.(P< 0/000) - (n:578) (n:699) P P (9 ) (387) ( 07) (628) < 0/000 23/±3/ 8 26/9± 4/ 5 < 0/ 000 23/5±4/ 3 29 /± 4/ 3 (kg/m 2 ) BMI < 0/000 83/±0/ 7 95/4± / 8 < 0/ 000 77/6±0/ 4 94/5± 9/ 7 (Cm) < 0/000 8/±5/ 3 38/7± 2/ 3 < 0/ 000 0/6±5/ 34/5± 23/ 6 (mmhg) < 0/000 76/5±0/ 4 85/9± / 9 < 0/ 000 72/9±9/ 5 84/6± 3/ 3 (mmhg < 0/000 05/9±35/ 2 22/5± 37/ 4 < 0/ 000 0/8±36/ 2 34 /± 4/ 6 (mg/dl) LDL-C < 0/000 70/3±39/ 3 200/6± 40/ 2 < 0/ 000 72/7±38/ 2 2/0± 46/ 9 (mg/dl) < 0/000 39/5±6/ 3 34/9± 4/ 7 < 0/ 000 4/2±6/ 7 38 /± 6/ 3 (mg/dl) HDL-C < 0/000 34/9±92/ 3 248/8± 4/ 0 < 0/ 000 08/4±59/ 6 27/9± 29/ (mg/dl) < 0/000 30/8±40/ 5 65/6± 4/ 5 < 0/ 000 3/5±39/ 7 72 /8± 48/ 7 (mg/dl) Non HDL-C

2 Non HDL : HDL -2 P (Odds ratio) < 0/000 / 8 < 0/000 / 04 < 0/000 / 26 BMI < 0/000 / 49 2 Non HDL-C Downloaded from ijdld.tums.ac.ir at 8:05 IRDT on Friday March 22nd 209 LDL -3 P (Odds ratio) < 0/009 / 39 < 0/000 / 04 < 0/000 / 26 BMI < 0/000 / 49 Non HDL-c. LDL Non HDL-c LDL %3 %38/2 LDL. Non HDL-c 5/ Non HDL (%95 CI :4/-6/2 P=0/00). 90 mg/dl Non HDL 2/6 LDL LDL (%95 CI :2/-3/2 P=0/0). 60 mg/dl Non HDL-C BMI.(2 ) BMI LDL-C.(3 ) Non HDL-c (%8/4 %36). Non HDL-c.[8-20] Non HDL-c LDL-C ATP %3 %2/2. Non HDL LDL-C. %3/9 %22.[].. [ 3 4] [] HDL [2] [3-5]. 2. LDL Non HDL-c %3/9 60. 90 Non HDL-c.

( 2 ) 0 389 -. 22 Downloaded from ijdld.tums.ac.ir at 8:05 IRDT on Friday March 22nd 209 Non HDL-c... Cook S, Weitzman M, Auinger P, Nguyen M, William H. Prevalence of a Metabolic Syndrome Phenotype in Adolescents, Findings From the Third National Health and Nutrition Examination Survey, 988-994. Arch Pediatr Adolesc Med 2003; 57: 82-827. 2. Sirtori C, Chapman MJ, Assmann G, Fruchart JC, Shepherd J, European Consensus Panel on HDL-C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004; 20: 253-68. 3. Packard CJ, Saito Y. Non HDL Cholesterol as a Measure of Atherosclerotic Risk. Journal of Atherosclerosis and Thrombosis 2004; : 6-4. 4. Lee KH, Son JC, Kim BT, Choi BH, Hye JS, Cha CK, et al. Non-HDL Cholesterol as a Risk Factor of Metabolic Syndrome in Korean Women. Korean J Obes 2007;6:02-0. 5. Daghri NM, Al-Attas OS, Al-Rubeaan K.The atherogenic and metabolicimpact of non-hdl cholesterol versus other lipid sub-components among non-diabetic and diabetic Saudis. Lipids Health Dis 2007; 6: 9. Published online 2007 April 4. doi: 0.86/476-5X-6-9. 6. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL. Non High-Density Lipoprotein Cholesterol Level as a Predictor of Cardiovascular Disease Mortality. Arch Intern Med 200; 6: 43-49. 7. Bittner V, Hardison R, Kelsey SF, Weiner BH, Jacobs AK, Sopko G. Bypass Angioplasty Revascularization Investigation. Nonhighdensity lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 2002; 06:2537-42. 8. Srinivasan SR, Frontini MG, Xu J, Berenson G S. Utility of Childhood Non High-Density Lipoprotein Cholesterol Levels in Predicting [2 22] apob [6 7] LDL. [0].[5] [6] Non HDL LDL. Adult Dyslipidemia and Other Cardiovascular Risks: The Bogalusa Heart Study. Pediatrics 2006; 8:20-206. 9. Srinivasan SR, Xu J, Rong T, Berenson GS. Usefulness of childhood non-high density lipoprotein cholesterol levels versus other lipoprotein measures in predicting adult subclinical atherosclerosis: The Bogalusa Heart Study. Pediatrics 2008; 2: 924-29..0. 30 384..63-53 :(4) 4. Azizi F, Rahmani M, Madjid M, Allahverdian S, Ghanbili J, Ghanbarian A, et al. Serum lipid levels in an Iranian population of children and adolescents: Tehran lipid and glucose study. Eur J Epidemiol 200; 7: 28-8...2 : 3 383..254-249 :(2) 3. Sharifi F, Mousavinasab SN, Soruri R, Saeini M, Dinmohammadi M. High Prevalence of Low High-Density Lipoprotein Cholesterol Concentrations and Other Dyslipidemic Phenotypes in an Iranian Population. Metabolic Syndrome and Related Disorders 2008; 6: 87-95. 4. Sharifi F, Mousavinasab SN, Saeini M, Dinmohammadi M. Prevalence of metabolic syndrome in an adult urban population of the west of Iran. Exp Diabetes Res 2009; 36505.

23 Non HDL : Downloaded from ijdld.tums.ac.ir at 8:05 IRDT on Friday March 22nd 209. 7-2 ATPIII.5 387.IDF.398-393 :(4) 7 6. Gardner CD, Winkleby MA, Fortmann SP. Population frequency distribution of non-high density lipoprotein cholesterol (Third National Health and Nutrition Examination Survey [NHANES III], 988-994). Am J Cardiol 2000; 86: 299-304. 7. Jiang R, Schulze MB, Li T, Rifai N, Stampfer MJ, Rimm EB, et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 2004; 27: 99-7. 8. Miller M, Ginsberg HN, Schaefer EJ. Relative Atherogenicity and Predictive Value of Non- High-Density Lipoprotein Cholesterol for Coronary Heart Disease. The American Journal of Cardiology 2008; 0:003-008. 9. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 06:343-42. 20. Bittner V. Non-high-density lipoprotein cholesterol and cardiovascular disease. Curr Opin Lipidol 2003; 4: 367-7. 2. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 200; 358: 2026-33. 22. Vega GL, Grundy SM. Does measurement of apolipoprotein B have a place in cholesterol management? [editorial]. Arteriosclerosis 990; 0: 668-7.